Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma

Rheumatology International

Volumn 28, Issue 2, 2007, Pages 179-183

  Simon, Zs ^a   Tarr, T ^a   Ress, Zs ^a   Gergely, L ^a   Kiss, E ^a   Illes, A ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Biological therapy; DLBCL; Lupus; Non Hodgkin lymphoma; Rituximab

Indexed keywords

AZATHIOPRINE; CEFEPIME; CHLOROQUINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCONAZOLE; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; B CELL LYMPHOMA; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REMISSION; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VASCULITIS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 36148970430     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0400-z     Document Type: Article

References (19)

1. Bernartsky S, Boivin JF, Joseph L, Rajan R, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal J L, Zummer M, Hanley J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, Pierre Y St, Ramsey-Goldman R, Clarke A (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52(5):1481-1490
2. Tarr T, Szekanecz E, Zeher M, Szegedi Gy, Kiss E (2006) The occurrence of malignancies in a Hungarian lupus population. Orv Hetil 46:2229-2233
3. Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520-535
4. McLaughlin P, Grillo-Lopez AJ, Link BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose tratment program. J Clin Oncol 16:2825-2833
5. Vose JM, Link BK, Grossbard ML (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, agressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397
6. Coiffier B, Lepage E, Briere PD (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242
7. Gergely L, Illes A, Nagy Zs, Adamkovich N, Rejto L, Szerafin L, Ujj Gy, Varoczy L, Radvanyi G, Borbenyi Z, Udvardy M (2004) Results of combination immuno-chemotherapy in treatment of diffuse large B cell lymphoma. Magy Belorv Arch 57:26-30
8. Eisenberg R (2003) Rituximab in lupus. Arthritis Res Ther 5:157-159
9. Kazkaz H, Isenberg D (2004) Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharm 4:398-402
10. Zintzaras E, Voulgarellis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmun diseases. Arch Intern Med 165:2337-2344
11. Ekström Smedby K, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundström C, Akerman M, Melbye M, Glimelius B, Adami HO (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Nat Cancer Inst 98(1):51-59
12. Thatayatikom A, White AJ (2006) Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5:18-24
13. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40ligand: an open-label trial. Arthritis Rheum 52:501-513
14. Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M (2005) Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after treatment with rituximab. Rheumatology (Oxford) 44:176-182
15. Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9):2635-2642
16. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459
17. Carton G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P (2002) Therapeutic activity os humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
18. Isenberg DA (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 77:24-28
19. Boumpas D, Sidiropoulos P, Bertsias G (2005) Optimum therapeutic approach for lupus nephritis: what therapy and whom? Nat Clin Pract Rheumatol 1:22-30